NEOS Investment Management LLC Has $120.08 Million Position in Gilead Sciences, Inc. $GILD

Posted by Brenda Bartman on Sep 4th, 2026

Gilead Sciences logo NEOS Investment Management LLC raised its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD – Free Report) by 11.3% in the second quarter, according to the company in its most recent disclosure with the SEC. The firm owned 950,430 shares of the biopharmaceutical company’s stock after acquiring an additional 96,425 shares during the quarter. NEOS Investment Management LLC owned approximately 0.08% of Gilead Sciences worth $120,077,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently made changes to their positions in the company. BlackRock Inc. bought a new position in Gilead Sciences during the 2nd quarter valued at about $15,393,785,000. Norges Bank bought a new stake in Gilead Sciences during the fourth quarter worth about $2,617,152,000. Legal & General Group Plc acquired a new stake in shares of Gilead Sciences during the second quarter worth approximately $1,316,606,000. Deutsche Bank AG acquired a new stake in shares of Gilead Sciences during the second quarter worth approximately $918,387,000. Finally, Boston Partners bought a new position in shares of Gilead Sciences in the fourth quarter valued at approximately $517,808,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

More Gilead Sciences News

Here are the key news stories impacting Gilead Sciences this week:

Positive Sentiment: Analysts raised Gilead’s earnings forecasts and upgraded the stock to “Strong Buy.” Zacks increased its 2027 quarterly EPS estimates and lifted its full-year forecast to $9.36 from $9.30. It also raised its FY2028 estimate to $9.66 from $9.58, suggesting expectations for improving profitability. Zacks upgrade and earnings estimates
Positive Sentiment: Gilead’s latest results provided a favorable foundation for the rally. The company reported quarterly revenue of $7.80 billion, above the $7.40 billion consensus estimate, while its loss per share was narrower than expected. Revenue increased 10.6% year over year, giving investors confidence in the business despite currently negative reported earnings. Gilead post-earnings performance
Positive Sentiment: A partner-backed stomach-cancer trial reached completion, creating a potential immuno-oncology catalyst. The milestone involving Arcus-supported research could provide important future data for Gilead’s oncology strategy, although the eventual investment impact depends on trial results and regulatory progress. Gilead cancer trial milestone
Neutral Sentiment: CEO Daniel O’Day sold 15,000 shares worth approximately $2.23 million. The sale reduced his ownership by 2.53%, but it was conducted under a pre-arranged Rule 10b5-1 trading plan, making it a limited bearish signal. SEC insider trading filing

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, insider Johanna Mercier sold 28,000 shares of the business’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $137.64, for a total transaction of $3,853,920.00. Following the completion of the sale, the insider directly owned 118,234 shares of the company’s stock, valued at approximately $16,273,727.76. The trade was a 19.15% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Anthony Welters sold 18,000 shares of the company’s stock in a transaction dated Wednesday, August 26th. The shares were sold at an average price of $148.62, for a total transaction of $2,675,160.00. Following the transaction, the director owned 12,894 shares in the company, valued at approximately $1,916,306.28. The trade was a 58.26% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 105,000 shares of company stock valued at $14,495,820 over the last ninety days. Company insiders own 0.30% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. HSBC raised Gilead Sciences from a “hold” rating to a “buy” rating and boosted their target price for the stock from $133.00 to $155.00 in a report on Monday, July 6th. Barclays cut their price objective on Gilead Sciences from $155.00 to $145.00 and set an “equal weight” rating for the company in a research report on Wednesday, July 29th. Royal Bank Of Canada boosted their price objective on Gilead Sciences from $120.00 to $123.00 and gave the stock a “sector perform” rating in a research note on Wednesday, August 5th. Weiss Ratings cut Gilead Sciences from a “buy (b-)” rating to a “hold (c-)” rating in a report on Tuesday, August 11th. Finally, Leerink Partners lowered Gilead Sciences from an “outperform” rating to a “market perform” rating and lowered their target price for the company from $146.00 to $127.00 in a research note on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $158.04.

Read Our Latest Research Report on GILD

Gilead Sciences Stock Performance

Shares of Gilead Sciences stock opened at $151.22 on Friday. The company has a debt-to-equity ratio of 2.03, a current ratio of 1.27 and a quick ratio of 1.09. The firm has a market cap of $187.51 billion, a P/E ratio of -56.64 and a beta of 0.33. The firm has a 50 day simple moving average of $136.21 and a 200 day simple moving average of $136.42. Gilead Sciences, Inc. has a fifty-two week low of $108.46 and a fifty-two week high of $157.29.

Gilead Sciences (NASDAQ:GILD – Get Free Report) last posted its quarterly earnings data on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping the consensus estimate of ($7.25) by $0.50. The firm had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%.The business’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.01 EPS. Sell-side analysts predict that Gilead Sciences, Inc. will post -0.48 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, September 29th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a dividend yield of 2.2%. The ex-dividend date of this dividend is Tuesday, September 15th. Gilead Sciences’s dividend payout ratio is -122.85%.

Gilead Sciences Profile

(Free Report)

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.